- Home
- MNTK vs EYPT Comparison
MNTK vs EYPT Comparison
Compare MNTK & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | EYPT |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 419.9M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MNTK | EYPT |
|---|---|---|
| Price | $2.27 | $3.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.80 | ★ $31.80 |
| AVG Volume (30 Days) | 336.3K | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,382,000.00 | $7,539,000.00 |
| Revenue This Year | $18.55 | N/A |
| Revenue Next Year | $12.68 | $3,115.57 |
| P/E Ratio | $146.00 | ★ N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.07 | $3.42 |
| 52 Week High | $2.73 | $19.11 |
Technical Indicators
Market Signals| Indicator | MNTK | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 31.98 |
| Support Level | $1.49 | $3.95 |
| Resistance Level | $2.73 | $14.72 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 54.19 | 39.33 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.